Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Bechtel

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Therapie|March 1, 1972
[Changes in the glycolytic enzyme activity of erythrocytes. II. Methodologic value for the trial of drugs in patients with cellular hypoxia]P Bechtel, P Grandmottet, A Magnin, et al.
Therapeutic Drug Monitoring|June 13, 2000
On the assessment of drug metabolism by assays of codeine and its main metabolitesE Haffen, G Paintaud, M Berard, et al.
Therapie|July 1, 1996
Effects of liver diseases on drug metabolismG Paintaud, Y Bechtel, M P Brientini, et al.
European Journal of Clinical Pharmacology|May 20, 1998
Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4O Monek, G Paintaud, Y Bechtel, et al.
Therapie|March 4, 2003
[Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism]Y Furet, Y Bechtel, C Le Guellec, et al.
Presse Medicale (Paris, France : 1983)|June 10, 1995
[Hematotoxicity caused by azathioprine genetically determined and aggravated by xanthine oxidase deficiency in a patient following renal transplantation]F Serre-Debeauvais, F Bayle, M Amirou, et al.
British Journal of Clinical Pharmacology|May 1, 1996
Inhibition of caffeine metabolism by 5-methoxypsoralen in patients with psoriasisE K Bendriss, Y Bechtel, A Bendriss, et al.
Therapie|January 1, 1996
[Bioavailability and tolerance of indomethacin as polymeric mini-capsules in man]C W Maboundou, G Paintaud, Y Ottignon, et al.
Therapie|January 1, 1993
[Collection of familial data in pharmacogenetics. Methodological problems]N Poisson, Y Bechtel, P De La Selle, et al.
Therapeutic Drug Monitoring|April 1, 1995
Stability of debrisoquine (CYP2D6) phenotype in liver transplant patientsA Bendriss, Y Bechtel, G Paintaud, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Therapie|March 1, 1972
[Changes in the glycolytic enzyme activity of erythrocytes. II. Methodologic value for the trial of drugs in patients with cellular hypoxia]P Bechtel, P Grandmottet, A Magnin, et al.
Therapeutic Drug Monitoring|June 13, 2000
On the assessment of drug metabolism by assays of codeine and its main metabolitesE Haffen, G Paintaud, M Berard, et al.
Therapie|July 1, 1996
Effects of liver diseases on drug metabolismG Paintaud, Y Bechtel, M P Brientini, et al.
European Journal of Clinical Pharmacology|May 20, 1998
Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4O Monek, G Paintaud, Y Bechtel, et al.
Therapie|March 4, 2003
[Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism]Y Furet, Y Bechtel, C Le Guellec, et al.
Presse Medicale (Paris, France : 1983)|June 10, 1995
[Hematotoxicity caused by azathioprine genetically determined and aggravated by xanthine oxidase deficiency in a patient following renal transplantation]F Serre-Debeauvais, F Bayle, M Amirou, et al.
British Journal of Clinical Pharmacology|May 1, 1996
Inhibition of caffeine metabolism by 5-methoxypsoralen in patients with psoriasisE K Bendriss, Y Bechtel, A Bendriss, et al.
Therapie|January 1, 1996
[Bioavailability and tolerance of indomethacin as polymeric mini-capsules in man]C W Maboundou, G Paintaud, Y Ottignon, et al.
Therapie|January 1, 1993
[Collection of familial data in pharmacogenetics. Methodological problems]N Poisson, Y Bechtel, P De La Selle, et al.
Therapeutic Drug Monitoring|April 1, 1995
Stability of debrisoquine (CYP2D6) phenotype in liver transplant patientsA Bendriss, Y Bechtel, G Paintaud, et al.
Pageof 2